BTZ has a boronic acid moiety that interacts with threonine residues in protease-active sites, and this moiety is capable of inhibiting the proteasome inside cancer cells, leading to cell death and inhibiting tumor growth. This evidence concerns the gene CASC3 and neoplasm.